Pursuant to SEBI Circular No. SEBI/HO/ISD/CIR/P/2020/135 dated July 23, 2020, Marksans Pharma has informed that it has enclosed the reporting of violations related to Code of Conduct under SEBI (PIT) Regulations, 2015 by two Designated Persons of the Company in the prescribed formats.
The above information is a part of company’s filings submitted to BSE.